-
Product Insights
Glomerulonephritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Glomerulonephritis - Drugs In Development, 2023’, provides an overview of the Glomerulonephritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Glomerulonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Mycobacterium tuberculosis Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Mycobacterium tuberculosis Infections - Drugs In Development, 2023’, provides an overview of the Mycobacterium tuberculosis Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mycobacterium tuberculosis Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Tuberculosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Tuberculosis - Drugs In Development, 2023’, provides an overview of the Tuberculosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Tuberculosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TSI-GSD-104 in Eastern Equine Encephalitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TSI-GSD-104 in Eastern Equine Encephalitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TSI-GSD-104 in Eastern Equine Encephalitis Drug Details: TSI-GSD-104 is under investigation...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine in Influenzavirus B Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine in Influenzavirus B Infections report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Influenza [strains...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IM-01 in Clostridioides difficile Infections (Clostridium difficile Associated Disease)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.IM-01 in Clostridioides difficile Infections (Clostridium difficile Associated Disease) Drug Details:IM-01 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine in Influenza A Virus, H1N1 Subtype Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine in Influenza A Virus, H1N1 Subtype Infections report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Influenza [Strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (Quadrivalent, Split Virion) Vaccine in Seasonal Influenza
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Influenza [Strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (Quadrivalent, Split Virion) Vaccine in Seasonal Influenza report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Ranpirnase in Anal Dysplasia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ranpirnase in Anal Dysplasia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Ranpirnase in Anal DysplasiaDrug Details:Ranpirnase (Onconase) is under development for the treatment of...
-
Macroeconomic Analysis
New Zealand PESTLE Insights – A Macroeconomic Outlook Report
Financial intermediation, real estate, and business activities contributed 33.9% to New Zealand’s gross value added (GVA) in 2022, followed by mining, manufacturing, and utilities (13.7%), and wholesale, retail, and hotels business activities (12.3%). In nominal terms, the three sectors are expected to grow by 7.1%, 7.2%, and 7.2%, respectively, in 2023. Auckland, Wellington, and Christchurch were home to 45.1% of New Zealand’s total population in 2022. Auckland remains the country’s most economically active region, contributing 32.6% to the country’s GDP...